ArticlePloS one2025
Homocysteine induces ferroptosis in cardiomyocytes by disrupting β-catenin/GPX4 pathway.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Homocysteine promotes ferroptosis through NCOA4-mediated ferritinophagy in THP-1 macrophages.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHomocysteine can cause damage to cardiomyocytes, but the exact mechanism underlying that injury is unknown. And, ferroptosis contributes to both the initiation and progression of cardiac diseases. This study aims to focus on homocysteine to investigate the involvement of β-catenin/GPX4 signaling in ferroptosis of cardiomyocytes.
methodsIn this study, C57BL/6 mice were utilized to establish an experimental model. Hyperhomocysteinemia was induced in the animal model by administering homocysteine at a concentration of 1.8 g/L in the drinking water. Model mice received the treatment of deferoxamine (DFO) and ferrostatin-1 (Fer-1) as therapeutic interventions. Western blot was utilized to detect β-catenin, FTH1, and GPX4. Lipid ROS, Fe2+, and GSH were detected by biochemical assays. In addition, β-catenin and GPX4 expression were assessed by immunostaining techniques. Cell viability was assessed using CCK-8 assay, and mitochondrial damage was examined by transmission electron microscopy. ChIP combining dual luciferase reporter gene assay was performed to analyze the interaction between β-catenin protein with the promoter of GPX4 gene.
resultsHomocysteine inhibited β-catenin activity and GPX4 expression, and promoted cardiomyocytes ferroptosis in vitro and in vivo. Overexpression of β-catenin promoted the expression of GPX4 and subsequently inhibited homocysteine-induced ferroptosis in cardiomyocytes. Further, results from the ChIP assay and dual-luciferase reporter assay indicated that GPX4 acted as a target gene of β-catenin.
conclusionHomocysteine induces ferroptosis in cardiomyocytes by disrupting β-catenin activity, subsequently downregulating its target gene, GPX4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.